Active, not recruitingPhase 2NCT04251715

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
OHSU Knight Cancer Institute
Principal Investigator
Skye C Mayo, MD, MPH
OHSU Knight Cancer Institute
Intervention
Dexamethasone(drug)
Enrollment
5 target
Eligibility
18 years · All sexes
Timeline
2021 – 2025

Study locations (1)

Collaborators

Oregon Health and Science University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04251715 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials